Evotec Nominates Dr. Wolfgang Hofmann to Supervisory Board, Reaches Agreement with MAK Capital

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company’s upcoming Annual General Meeting (AGM) on June 11, 2026. The move is part of a broader effort to strengthen oversight and governance capabilities as the company implements its transformation plans to grow shareholder value.

The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the size of the Supervisory Board from six to seven members. The expansion is intended to support effective oversight and long-term value creation.

In a separate but related development, Evotec has entered into a cooperation agreement with MAK Capital Fund LP (‘MAK Capital’), a key shareholder. Under the terms of the agreement, MAK Capital has agreed to customary voting and cooperation commitments. The agreement follows constructive discussions between the company and the investor, reflecting Evotec’s commitment to open shareholder dialogue.

Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board, said: ‘We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached reflects Evotec’s commitment to constructive shareholder engagement, supporting the long‑term success of the Company.’

Michael A. Kaufman, Chief Executive Officer of MAK Capital, said: ‘We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec’s ongoing transformation.’

Evotec is a life science company pioneering drug discovery and development. The company integrates breakthrough science with AI-driven innovation and advanced technologies, focusing on small molecules, biologics, cell therapies, and associated modalities. Evotec’s portfolio includes over 100 proprietary R&D assets, most of which are co-owned, targeting therapeutic areas such as oncology, cardiovascular and metabolic diseases, neurology, and immunology. The company employs more than 4,500 experts across sites in Europe and the U.S.

The nomination of Dr. Hofmann and the agreement with MAK Capital signal a commitment to robust governance and shareholder alignment, which are critical as Evotec navigates its transformation. The cooperation agreement ensures that a major shareholder supports the company’s strategic direction, potentially reducing uncertainty and fostering a more stable environment for long-term growth. The expansion of the Supervisory Board also suggests a proactive approach to oversight, which could enhance decision-making and accountability.

Investors will be watching the AGM closely, as the proposed changes to the Supervisory Board and the cooperation agreement with MAK Capital could have significant implications for Evotec’s governance structure and strategic execution. The company’s focus on transformation and value creation remains central to its narrative, and these developments are likely to be viewed as positive steps toward achieving those goals.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Evotec Nominates Dr. Wolfgang Hofmann to Supervisory Board, Reaches Agreement with MAK Capital.

The post Evotec Nominates Dr. Wolfgang Hofmann to Supervisory Board, Reaches Agreement with MAK Capital appeared first on citybuzz.